Drug Profile
Research programme: cancer immunotherapeutics - Chinook Therapeutics/Merck
Latest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator BioNovion
- Developer Chinook Therapeutics; Merck Sharp & Dohme
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer